Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asian CROs On The March, But Tie-Ups Carry Risk: Analyst

This article was originally published in PharmAsia News

Executive Summary

SAN FRANCISCO - Pointing to the potential for a "perfect storm" in China and Asia with regard to contract research organizations' growth, Lehman Brothers analyst Douglas Tsao switched his metaphor to bolster the warning

You may also be interested in...



Merck China CEO Michel Vounatsos And Emerging Markets R&D Senior VP RuiPing Dong On Provincial Management: An Interview With PharmAsia News

Merck & Co. Inc. CEO Kenneth Frazier was the keynote speaker at the China Healthcare Investment Conference in Beijing March 23, stressing that his trip highlighted the place the Chinese market holds for the company's growth. After the conference, Merck, Sharpe and Dohme China President Michel Vounatsos and Merck Research Laboratory Senior VP for Emerging Markets RuiPing Dong spoke with PharmAsia News about navigating China's provincial markets and fitting China into a global R&D strategy.

Merck China CEO Michel Vounatsos And Emerging Markets R&D Senior VP RuiPing Dong On Provincial Management: An Interview With PharmAsia News

Merck & Co. Inc. CEO Kenneth Frazier was the keynote speaker at the China Healthcare Investment Conference in Beijing March 23, stressing that his trip highlighted the place the Chinese market holds for the company's growth. After the conference, Merck, Sharpe and Dohme China President Michel Vounatsos and Merck Research Laboratory Senior VP for Emerging Markets RuiPing Dong spoke with PharmAsia News about navigating China's provincial markets and fitting China into a global R&D strategy.

Pfizer, Lilly And Merck Strike Up Cancer Research Partnership In Asia

Eli Lilly, Pfizer and Merck - like many Big Pharma - are hoping to spur growth in the future by addressing unmet medical need in Asia's emerging markets. The three companies hope to accelerate research in addressing Asia's most-commonly diagnosed cancers with a non-competitive collaboration - perhaps the first of its kind in the region - to share data for the next several years

Related Content

UsernamePublicRestriction

Register

LL1130496

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel